← Leaderboards
Richard W Scott
Polymedix, Inc,
$15,242,805
Attributed
$16,480,803
Total exposure
13
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2006–18$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$16,480,803 · 13
By mechanism
R44$15,574,139 · 7
R43$906,664 · 6
Top collaborators
- Gill Diamond4 shared
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseIn VitroToxic EffectLeadIn VivoResistancePropertySafetyProteinsInfectionCytotoxicityDesignDoseSeriesPharmaceutical PreparationsPharmaceutical ChemistryPeptidesDrug KineticsAnimalsEnzymesDrug ResistanceStructureCellsPrograms
Grant awards (25)
DEVELOPMENT OF TOPICAL ANTIVIRAL AGENTS FOR TREATING MOLLUSCUM CONTAGIOSUM$998,623
R44 · FY2018 · AI · contact PI
DEVELOPMENT OF TOPICAL ANTIVIRAL AGENTS FOR TREATING MOLLUSCUM CONTAGIOSUM$1,002,225
R44 · FY2017 · AI · contact PI
Development of Small Molecule Therapeutics Against Smallpox and Other Poxviruses$1,197,020
R44 · FY2016 · AI · contact PI
DEVELOPMENT OF TOPICAL ANTIVIRAL AGENTS FOR TREATING MOLLUSCUM CONTAGIOSUM$1,002,030
R44 · FY2016 · AI · contact PI
Development of Small Molecule Therapeutics Against Smallpox and Other Poxviruses$1,110,810
R44 · FY2015 · AI · contact PI
A Novel Therapeutic for Invasive Candidiasis$750,000
R44 · FY2015 · AI · contact PI
Development of Small Antimicrobial Peptide Mimics as Drug-Resistant and Susceptib$1,000,000
R44 · FY2014 · AI · contact PI
A Novel Therapeutic for Invasive Candidiasis$750,000
R44 · FY2014 · AI · contact PI
Development of Small Antimicrobial Peptide Mimics as Drug-Resistant and Susceptib$1,000,000
R44 · FY2013 · AI · contact PI
Development of Small Antimicrobial Peptide Mimics as Drug-Resistant and Susceptib$1,000,000
R44 · FY2012 · AI · contact PI
A Topical Host Defense Peptide Mimetic for Oral Mucositis$161,376
R43 · FY2012 · CA · contact PI
Development of Small Antimicrobial Peptide Mimics as Drug-Resistant and Susceptib$499,244
R44 · FY2011 · AI · contact PI
A Novel Antimicrobial Mimetic for Oral Candidiasis$490,539
R44 · FY2011 · DE · contact PI
Development of Small Antimicrobial Peptide Mimics as Drug-Resistant and Susceptib$499,850
R44 · FY2010 · AI · contact PI
A Novel Antimicrobial Mimetic for Oral Candidiasis$485,458
R44 · FY2010 · DE · contact PI
Development of biomimetic oligomers as anticoagulant antagonists$369,685
R44 · FY2010 · HL · contact PI
Development of biomimetic oligomers as anticoagulant antagonists$553,390
R44 · FY2009 · HL · contact PI
Therapeutic Development of Antimicrobial Biomimetics$867,200
R44 · FY2008 · AI · contact PI
A Novel Antimicrobial Peptide Mimetic For Oral Candidiasis$125,600
R43 · FY2008 · DE · contact PI
Therapeutic Development of Antimicrobial Biomimetics$998,970
R44 · FY2007 · AI · contact PI
Development of biomimetic oligomers as anti-coagulant antagonists$100,000
R43 · FY2007 · HL · contact PI
Therapeutic Development of Antimicrobial Biomimetics$999,095
R44 · FY2006 · AI · contact PI
Animal Testing of Biomimetic Antimicrobial Oligomers$238,800
R43 · FY2004 · AI
Biomimetic antimicrobials for biowarfare pathogens$167,650
R43 · FY2004 · AI
Biomimetic Polymers for an Antiseptic Handwash$113,238
R43 · FY2004 · AI